Skip to main content
. 2019 Dec 8;25:9346–9356. doi: 10.12659/MSM.917287

Figure 5.

Figure 5

SYK mediated peritoneal fibrosis by regulating the TGF-β1/Smad3 signaling. Data show the changes after the use of the SYK inhibitor or the TGF-β signaling inhibitor. (A) Abnormal hyperplasia of the peritoneal tissue is reduced. Scale bar, 500 μm. (B) The expression of SYK in peritoneal tissues is significantly reduced. Scale bar, 500 μm. (C) Upregulation of SYK is inhibited, as in Figure A. ** P<0.01 vs. sham. * P<0.05 vs. chlorhexidine digluconate. (D) Significant inhibition of the expression of inflammatory cytokines. ** P<0.01 and *** P<0.001 vs. sham. * P<0.05 and ** P<0.01 vs. chlorhexidine digluconate. (E) Phosphorylation of SYK is inhibited and also blocks the activation of TGF-β signaling. ** P<0.01 and *** P<0.001 vs. sham. * P<0.05, ** P<0.01 and *** P<0.001 vs. chlorhexidine digluconate. All experiments were independently conducted in triplicate. CG – chlorhexidine digluconate.